[Dapsone-induced decrease in the HbA(1c) level may cause artefacts in diabetic control]

Ugeskr Laeger. 2013 Feb 18;175(8):505-6.
[Article in Danish]

Abstract

Glycated haemoglobin (HbA(1c)) level is used to monitor glycaemic control in diabetic patients, and has recently been included as a diagnostic factor for type 2 diabetes mellitus (DM). A 50-year-old male with well-controlled type 1 DM, Mb Addison and coeliac disease was diagnosed with dermatitis herpetiformis and treated with dapsone. Subsequently, the patient presented a pronounced drop in HbA(1c) levels without changes in blood glucose levels. S-fructosamine values were in agreement with the previous stable HbA(1c) values. Blood analyses showed inappropriately low HbA(1c) values due to mild haemolysis and shortening of erythrocyte lifetime without anaemia.

Publication types

  • Case Reports

MeSH terms

  • Anti-Infective Agents / administration & dosage
  • Anti-Infective Agents / adverse effects*
  • Anti-Infective Agents / therapeutic use
  • Dapsone / administration & dosage
  • Dapsone / adverse effects*
  • Dapsone / therapeutic use
  • Dermatitis Herpetiformis / drug therapy
  • Diabetes Mellitus, Type 1 / blood
  • Glycated Hemoglobin / analysis
  • Glycated Hemoglobin / drug effects*
  • Glycated Hemoglobin / metabolism
  • Hemolysis / drug effects
  • Humans
  • Male
  • Middle Aged

Substances

  • Anti-Infective Agents
  • Glycated Hemoglobin A
  • hemoglobin A1c protein, human
  • Dapsone